Treatment of pediatric anxiety disorders

Rapp, Amy M.; Dodds, Alice; Walkup, John T.; Rynn, Moira A.

doi:10.1111/nyas.12318

Cited by 14 publications

(18 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…61,62 For adults, evidence-based pharmacotherapies are also available. These include benzodiazepine receptor agonist (BzRA) hypnotics (e.g., zolpidem, eszopiclone, zaleplon, temazepam, flurazepam, estazolam), doxepin, ramelteon, and suvorexant.…”

Section: Descriptionmentioning

confidence: 99%

Quality Measures for the Care of Patients with Insomnia

Edinger

Buysse

Deriy

et al. 2015

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

The American Academy of Sleep Medicine (AASM) commissioned fi ve Workgroups to develop quality measures to optimize management and care for patients with common sleep disorders including insomnia. Following the AASM process for quality measure development, this document describes measurement methods for two desirable outcomes of therapy, improving sleep quality or satisfaction, and improving daytime function, and for four processes important to achieving these goals. To achieve the outcome of improving sleep quality or satisfaction, pre-and post-treatment assessment of sleep quality or satisfaction and providing an evidence-based treatment are recommended. To realize the outcome of improving daytime functioning, pre-and post-treatment assessment of daytime functioning, provision of an evidence-based treatment, and assessment of treatment-related side effects are recommended. All insomnia measures described in this report were developed by the Insomnia Quality Measures Workgroup and approved by the AASM Quality Measures Task Force and the AASM Board of Directors. The AASM recommends the use of these measures as part of quality improvement programs that will enhance the ability to improve care for patients with insomnia. Citation: Edinger JD, Buysse DJ, Deriy L, Germain A, Lewin DS, Ong JC, Morgenthaler TI. Quality measures for the care of patients with insomnia. J Clin Sleep Med 2015;11(3):311-334.pii: jc-00028-15 http://dx.doi.org/10.5664/jcsm.4552 I nsomnia is the most prevalent sleep disorder, and it has signifi cant consequences for health and function. Effi cacious treatments exist. However, the approach to management of insomnia is not standardized, particularly outside of sleep medicine centers. The aim of this paper is to describe the development of quality measures that can be applied to the management of insomnia patients across a wide range of ages and care settings.Insomnia is characterized by diffi culties initiating, sustaining, or obtaining qualitatively satisfying sleep despite adequate sleep opportunities and circumstances, resulting in impaired daytime functioning.1,2 Insomnia can occur across the majority of the human lifespan, from childhood years to old age. Over 33% of adults experience insomnia at least intermittently, whereas 10% to 22% suffer chronic sleep diffi culties.3-8 While prevalence data are more sparse for younger age groups, insomnia symptoms may be seen in as many as 20% to 40% children and teenagers, with slightly higher rates among girls and those with symptoms of mood disturbance. 9,10 While its signifi cance is often minimized, 11,12 persistent insomnia is associated with daytime fatigue, decreased mood, impairment in social/vocational functioning or poor school performance, and reduced quality of life.1,2,13-15 Insomnia also increases the risks for serious medical disorders, traffi c and work-site accidents, alcohol/drug abuse, and major psychiatric illnesses. 4,[16][17][18][19][20][21][22] When insomnia is comorbid with a psychiatric illness such as major depression, it c...

show abstract

Section: Descriptionmentioning

confidence: 99%

Quality Measures for the Care of Patients with Insomnia

Edinger

Buysse

Deriy

et al. 2015

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…Selective serotonin reuptake inhibitors do not appear to have an additive effect in the treatment of obsessive-compulsive disorder (OCD) if used in conjunction with exposure-based CBT [30]. Memantine, a noncompetitive antagonist of the NMDA receptor thought to protect neurons from the neurotoxic impact of glutamate, has had some promising treatment results for those whose OCD is refractory to other treatments [31,32].…”

Section: Pharmacological Treatment Options For Pediatric Anxiety Disomentioning

confidence: 99%

“…Pharmacotherapy should be considered if comorbid disorders are present, if there is a partial response to therapy, or if the symptoms increase in severity and a reduction in symptoms is needed to make progress in therapy. Recent randomized controlled trials have reported that treatment response is improved if both pharmacological and cognitive behavioral therapies are applied to the reduction of symptoms of anxiety [30].…”

Section: The American Academy Of Child and Adolescent Psychiatry Treamentioning

confidence: 99%

“…Selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment for anxiety disorders in youth [30,31]. Selective serotonin reuptake inhibitors do not appear to have an additive effect in the treatment of obsessive-compulsive disorder (OCD) if used in conjunction with exposure-based CBT [30].…”

Section: Pharmacological Treatment Options For Pediatric Anxiety Disomentioning

confidence: 99%

See 1 more Smart Citation

Treating anxiety disorders in children and adolescents with epilepsy: What do we know?

Jones¹

2014

Epilepsy & Behavior

View full text Add to dashboard Cite

“…First, our working hypothesis for the mechanism of brain dysfunction induced by PNE is supported by the behavioral and pharmacological experiments with DCS as discussed above. Second, and most importantly, our findings also suggest that NMDA receptor partial agonists may be a novel and effective treatment for impaired attentional function, behavioral flexibility, and anxiety in patients with AD/HD or schizophrenia (Chue and Lalonde, 2014;Rapp et al, 2013). Accordingly, further studies using the PNE mouse model are warranted to clarify the pathophysiology and to provide the conceptual framework for drug discovery in neuropsychiatric disorders such as AD/HD and schizophrenia.…”

Section: Prenatal Nicotine Exposure Impairs Corticogenesismentioning

confidence: 99%

Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex

Aoyama

Toriumi

Mouri

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Cigarette smoking during pregnancy is associated with various disabilities in the offspring such as attention deficit/hyperactivity disorder, learning disabilities, and persistent anxiety. We have reported that nicotine exposure in female mice during pregnancy, in particular from embryonic day 14 (E14) to postnatal day 0 (P0), induces long-lasting behavioral deficits in offspring. However, the mechanism by which prenatal nicotine exposure (PNE) affects neurodevelopment, resulting in behavioral deficits, has remained unclear. Here, we report that PNE disrupted the proliferation of neuronal progenitors, leading to a decrease in the progenitor pool in the ventricular and subventricular zones. In addition, using a cumulative 5-bromo-2 0 -deoxyuridine labeling assay, we evaluated the rate of cell cycle progression causing the impairment of neuronal progenitor proliferation, and uncovered anomalous cell cycle kinetics in mice with PNE. Accordingly, the density of glutamatergic neurons in the medial prefrontal cortex (medial PFC) was reduced, implying glutamatergic dysregulation. Mice with PNE exhibited behavioral impairments in attentional function and behavioral flexibility in adulthood, and the deficits were ameliorated by microinjection of D-cycloserine into the PFC. Collectively, our findings suggest that PNE affects the proliferation and maturation of progenitor cells to glutamatergic neuron during neurodevelopment in the medial PFC, which may be associated with cognitive deficits in the offspring.

show abstract

Treatment of pediatric anxiety disorders

Cited by 14 publications

References 65 publications

Quality Measures for the Care of Patients with Insomnia

Quality Measures for the Care of Patients with Insomnia

Treating anxiety disorders in children and adolescents with epilepsy: What do we know?

Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex

Contact Info

Product

Resources

About